JGJonathan C. Giang

Jonathan C. Giang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonathan C. Giang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Mina S. Makary

    Department of Radiology, The Ohio State University Medical Center, Columbus, OH 43210, USA

    2 shared publications
  • Mustaqueem Pallumeera

    The Ohio State University College of Medicine, Columbus, OH 43210, USA

    2 shared publications
  • Ben Varughese

    Section of Vascular and Interventional Radiology, Department of Radiology, University of Washington, Seattle, USA

    1 shared publication
  • David S. Shin

    Section of Vascular and Interventional Radiology, Department of Radiology, University of Washington, Seattle, USA

    1 shared publication
  • Jeffrey Forris Beecham Chick

    Section of Vascular and Interventional Radiology, Department of Radiology, University of Washington, Seattle, USA

    1 shared publication
  • John Weaver

    Section of Vascular and Interventional Radiology, Department of Radiology, University of Washington, Seattle, USA

    1 shared publication

Latest Publications

  • Open Access

    Iatrogenic injury to an unusual anatomic variant of the internal thoracic artery: lateral costal artery

    by Zhonghao Cui, David S. Shin, Jonathan C. Giang, Jeffrey Forris Beecham Chick, Ben Varughese, John Weaver, Mina S. Makary

  • Open Access

    Histotripsy: Recent Advances, Clinical Applications, and Future Prospects

    by Mustaqueem Pallumeera, Marcus Hong, Jonathan C Giang, Mina S Makary

    Histotripsy is a novel, non-invasive ultrasound-based ablative therapy that destroys tissue through focused cavitation. As solid tumors continue to be a major global health burden, there is interest in image-guided ablation techniques that reduce collateral damage and promote immune activation. This narrative review aims to synthesize current advancements, clinical applications, limitations, and future directions of histotripsy in both oncologic and non-oncologic contexts. A comprehensive literature search was conducted from database inception to July 2025. Search terms included combinations of subject headings and keywords such as “histotripsy,” “mechanical ablation,” “ultrasound,” and “solid tumors.” Boolean operators and truncation were used to increase sensitivity. Peer-reviewed studies were included, encompassing preclinical, clinical, and review articles. Reference lists of relevant articles were examined to identify additional sources. Histotripsy has shown strong potential in the treatment of tumors involving the liver, pancreas, kidney, brain, and cardiovascular system. It offers real-time imaging guidance, sharp lesion boundaries, and minimal damage to surrounding structures. Early clinical trials have demonstrated encouraging safety and efficacy, particularly in liver and kidney tumors. Its ability to preserve critical anatomy and stimulate innate and adaptive immune responses through the release of cellular debris and cytokines offers advantages over thermal ablation. Limitations include acoustic aberration, motion-related targeting challenges, and the need for further long-term clinical data. Histotripsy represents a promising advancement in noninvasive tumor ablation. Continued clinical investigation and technological refinement are necessary to validate its therapeutic value and define its role within comprehensive cancer care.


  • Top Cited Papers
    Open Access

    Evolving and Novel Applications of Artificial Intelligence in Cancer Imaging

    by Mustaqueem Pallumeera, Jonathan C. Giang, Ramanpreet Singh, Nooruddin S. Pracha, Mina S. Makary

    Artificial intelligence (AI) is revolutionizing cancer imaging, enhancing screening, diagnosis, and treatment options for clinicians. AI-driven applications, particularly deep learning and machine learning, excel in risk assessment, tumor detection, classification, and predictive treatment prognosis. Machine learning algorithms, especially deep learning frameworks, improve lesion characterization and automated segmentation, leading to enhanced radiomic feature extraction and delineation. Radiomics, which quantifies imaging features, offers personalized treatment response predictions across various imaging modalities. AI models also facilitate technological improvements in non-diagnostic tasks, such as image optimization and automated medical reporting. Despite advancements, challenges persist in integrating AI into healthcare, tracking accurate data, and ensuring patient privacy. Validation through clinician input and multi-institutional studies is essential for patient safety and model generalizability. This requires support from radiologists worldwide and consideration of complex regulatory processes. Future directions include elaborating on existing optimizations, integrating advanced AI techniques, improving patient-centric medicine, and expanding healthcare accessibility. AI can enhance cancer imaging, optimizing precision medicine and improving patient outcomes. Ongoing multidisciplinary collaboration between radiologists, oncologists, software developers, and regulatory bodies is crucial for AI’s growing role in clinical oncology. This review aims to provide an overview of the applications of AI in oncologic imaging while also discussing their limitations.